Ramalingam SS, Maitland M, Frankel P, et al. Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of ...
About the Series: The Current Multidisciplinary Oncology series edited by Charles R. Thomas consolidates and integrates the varied aspects of multidisciplinary care for major topics in oncology, including breast, lung, prostrate, head and ...
Tiny dots may be tattooed on your skin to mark the center and corners of your field. ... It is important that you do not wash the marks off until all the treatments are completed. These marks stay on best if they are not allowed to get ...
Yanagawa H, Sone S, Takahashi Y, et al. Serum levels of interleukin 6 in ... Shao F, Li J, Fine J, Wong WK, Pencina M. Inference for reclassification statistics under nested and non-nested models for biomarker evaluation. Biomarkers.
Goetz Kloecker, Mostafa Fraig, Susanne M. Arnold, Cesar A. Perez ... 201 Victor van Berkel, MD, PhD, Michael J. Carr, MD, MS, Neal E. Dunlap, MD, Matthew Fox, MD, Ignacio Gil-Bazo, MD, PhD, Rohit Kumar, MD, Katy Alyse Marino, MD, ...
The key to a cure or successful management of lung cancer is getting the best treatment as soon as possible. The oldest and most effective treatment for cancer is surgery. The goal of surgery is to achieve a complete cure by removing ...
In Lung Cancer: From Diagnosis to Treatment, Dr. Scott helps you understand the process—from getting a diagnosis to going through treatment.
He has been recognized as a Top Doctor in Philadelphia and as one of America's Top Doctors for Cancer Treatment (Thoracic Surgery) by Castle Connolly, Sixth Edition. Dr. Scott's research interests include the use of positron emission ...
Because lung cancer can take years to develop, it is mostly found in people over 65 years of age. When lung cancer spreads to other parts of the body, only about 2 percent of patients are still living five years after the diagnosis.
Together, the two volumes constitute an unprecedented resource for those who wish to better understand how this disease is being diagnosed and treated and what novel techniques may be available to improve both processes.
This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical ...
However, since the first edition of Lung Cancer was published 14 years ago, rapid progress in the biology, prevention, diagnosis, and treatment of the disease has been made.
Lung cancer is one of the biggest challenges in oncology today.
Lung cancer kills more women than breast cancer, more men than prostate cancer. This authoritative book presents new lifesaving strategies for those already diagnosed and those at risk (including ex-smokers).
This Fourth Edition of Lung Cancer: Provides the very latest research in the identification of biomarkers to predict a high risk for developing lung cancer – vital for implementing screening, diagnosis, and prevention strategies Presents ...
This likewise makes it bound to react to chemotherapy. However, it's likewise less inclined to be restored with treatment. At times, lung cancer tumors contain both NSCLC and SCLC cells. Mesothelioma is another type of lung cancer.
Lung cancer is the most common cause of death from cancer worldwide – it is estimated to cause nearly one in five cancer deaths.
A multidisciplinary team approach is now considered the most effective way to manage lung cancer. Imaging plays a central role in this multidisciplinary approach; this is reflected in the present volume.
Lung cancer is the most common form of cancer in the world and a major cause of death. This new book brings together stellar research from around the world.
The aim of this book is to provide an exciting read on strategies in the diagnosis and therapy of lung cancer.